White Y S, Johnson P J, Davison F, Williams R
Liver Unit, King's College Hospital School of Medicine and Dentistry, London, UK.
Br J Cancer. 1990 Jun;61(6):909-12. doi: 10.1038/bjc.1990.203.
As part of a larger study designed to investigate the interaction of factors such as cirrhosis and hepatitis B virus infection as aetiological agents in the development of hepatocellular carcinoma, we investigated the status of hepatic HBV-DNA sequences in 156 cirrhotic patients. Forty-one were HBsAg seropositive and 18 (44%) of these had HBV-DNA sequences detectable in their livers. There are also 26 subjects who showed markers of a previous HBV infection (anti-HBs/anti-HBc), only one (4%) of whom had demonstrable hepatic HBV-DNA sequences. No sequences were found in any of the remaining 89 patients who were seronegative for all markers. Thus, liver HBV-DNA was only detected in the presence of a serum marker, usually HBsAg.
作为一项旨在研究诸如肝硬化和乙肝病毒感染等因素作为肝细胞癌病因学因素之间相互作用的更大规模研究的一部分,我们调查了156例肝硬化患者肝脏中乙肝病毒脱氧核糖核酸(HBV-DNA)序列的情况。41例患者乙肝表面抗原(HBsAg)血清学阳性,其中18例(44%)肝脏中可检测到HBV-DNA序列。还有26例患者显示既往乙肝病毒感染的标志物(抗-HBs/抗-HBc),其中只有1例(4%)肝脏中有可证实的HBV-DNA序列。在其余89例所有标志物血清学阴性的患者中均未发现序列。因此,肝脏HBV-DNA仅在存在血清标志物(通常为HBsAg)时才可检测到。